Fast Five Quiz: Glycemic Control in Type 2 Diabetes

Romesh Khardori, MD, PhD


January 12, 2022

A sodium-glucose cotransporter 2 (SGLT2) inhibitor with proven benefit for the specific comorbidity is recommended as part of the glucose-lowering regimen for patients with type 2 diabetes who have established atherosclerotic cardiovascular disease or indicators of high risk, established kidney disease, or heart failure. Data from several cardiovascular outcomes trials have provided evidence of cardiovascular benefits from the use of certain SGLT2 inhibitors and glucagon-like peptide 1 receptor agonists. Similarly, some of these drugs have also been recently shown to have beneficial renal effects as well. Therefore, it is important to think of these comorbidities when making treatment decisions.

So far, there has been no evidence of similar cardiovascular or renal benefits of lowering glucose using older therapies indicated for patients with type 2 diabetes, such as metformin, sulfonylureas, thiazolidinediones, or insulin, or for the newer dipeptidyl peptidase 4 inhibitors.

Learn more about cardiovascular risk management in type 2 diabetes.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.